Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

The following is a summary of “Association Between Patient Perception of Disease Status and Different Components of the ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...